Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

CPI-0209 in Combination with Carboplatin for the Treatment of Patients with Platinum Sensitive Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Trial Status: active

This phase I trial tests the safety, side effects, and best dose of CPI-0209 in combination with carboplatin in treating patients with ovarian, fallopian tube or primary peritoneal cancer that has responded to previous treatment with a platinum-based drug (platinum-sensitive) and has come back after a period of improvement (recurrent). CPI-0209, a small molecule drug, acts by blocking the activity of two forms of a protein called enhancer of zeste homolog (EZH) methyltransferase, EZH2 and EZH1, and may prevent tumor cells from growing. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. CPI-0209 in combination with carboplatin may be safe, tolerable and/or effective in treating patients with platinum sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.